Evidence map›Paper›PMID 34653632›Full record

ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2022

Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer.

L Federico, D J McGrail, S-E Bentebibel, C Haymaker, A Ravelli, M-A Forget, T Karpinets, P Jiang, A Reuben, M V Negrao and 27 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of oncology : official journal of the European Society for Medical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 1 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 1 synthesis or guideline pooled it, 128 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Therapeutic vaccines for NSCLC: From mechanisms to clinical translation.Chinese medical journal pulmonary and critical care medicine · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

37 authors at 2 institutions in 3 countries.

L FedericoTherapeutics Discovery Division, The University of Texas MD Anderson Cancer Center, Houston, USA.
D J McGrailDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA.
S-E BentebibelDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
C HaymakerDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
A RavelliDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
M-A ForgetDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
T KarpinetsDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
P JiangDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
A ReubenDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
M V NegraoDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
J LiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
R KhairullahDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
J ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
A WeissferdtDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
A A VaporciyanDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA.
M B AntonoffDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA.
G WalshDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA.
S-Y LinDepartment of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, USA.
A FutrealDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.
I WistubaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
J RothDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA.
L A ByersDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
P-O GaudreauDepartment of Oncology, Queens' University and the Canadian Cancer Trials Group, Kingston, Canada.
N UraokaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
A F CruzDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
H DejimaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
R N LazcanoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
L M SolisDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
E R ParraDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, USA.
J J LeeDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA.
S SwisherDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA.
T CasconeDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
J V HeymachDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
J ZhangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: jzhang20@mdanderson.org.
B SepesiDepartment of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: bsepesi@mdanderson.org.
D L GibbonsDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA; Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: dlgibbon@mdanderson.org.
C BernatchezDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: cbernatchez@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USQueen's University · CA

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4M
Determining the Immunological Consequences of DNA Replication Stress Response Defects in Renal Cells Carcinoma to Improve Immunotherapy OutcomesK99CA240689 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MCGRAIL, DANIEL JAMES · 2019 to 2020
$207k
NCI NIH HHS K99 CA240689NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907
6 · The paper itself

Abstract

backgroundDespite the importance of tumor-infiltrating T lymphocytes (TILs) in cancer biology, the relationship between TIL phenotypes and their prognostic relevance for localized non-small-cell lung cancer (NSCLC) has not been well established. PATIENTS AND

methodsFresh tumor and normal adjacent tissue was prospectively collected from 150 patients with localized NSCLC. Tissue was comprehensively characterized by high-dimensional flow cytometry of TILs integrated with immunogenomic data from multiplex immunofluorescence, T-cell receptor sequencing, exome sequencing, RNA sequencing, targeted proteomics, and clinicopathologic features.

resultsWhile neither the magnitude of TIL infiltration nor specific TIL subsets were significantly prognostic alone, the integration of high-dimensional flow cytometry data identified two major immunotypes (IM1 and IM2) that were predictive of recurrence-free survival independent of clinical characteristics. IM2 was associated with poor prognosis and characterized by the presence of proliferating TILs expressing cluster of differentiation 103, programmed cell death protein 1, T-cell immunoglobulin and mucin-domain containing protein 3, and inducible T-cell costimulator. Conversely, IM1 was associated with good prognosis and differentiated by an abundance of CD8

conclusionsOur study suggests that although the number of infiltrating T cells is not associated with patient survival, the nature of the infiltrating T cells, resolved in distinct TIL immunotypes, is prognostically relevant in NSCLC and may inform therapeutic approaches to clinical care.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsCD8-Positive T-LymphocytesHumansLymphocytes, Tumor-InfiltratingPrognosisbiomarkersimmune systemlung cancermicroenvironmentT cells

Identifiers

PMID34653632
PMCPMC10019222
OpenAlexW3200214671

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.